Atai Life Sciences announces the launch of a new intranasal drug delivery system, InnarisBio, based on sol-gel technology.
MindMed Announces Initiation of Phase 1 Clinical Trial of Intravenous DMT
MindMed is preparing to commence a Phase I clinical trial on the safety/tolerance of intravenous DMT.
TSI EDITOR |
2021-07-28
Cybin Announces Size and Pricing of Previously Announced Overnight Marketed Public Offering of Common Shares
Cybin's new financing is priced at CAD$3.40. The Company intends to issue 8.8 million new units for total proceeds of CAD$30 million.
TSI EDITOR |
2021-07-28
Will The Covid-19 Pandemic Be A Turning Point For Psychedelic Medicine?
The Mental Health Crisis has been ignored for decades. Covid-19 has made this mental health catastrophe much worse -- and people are now starting to notice.
TSI EDITOR |
2021-07-28
Cybin Announces Overnight Marketed Public Offering of Common Shares
Cybin Inc is seeking to raise capital with an overnight offering of common shares. Pricing and size of the offering to be determined.
TSI EDITOR |
2021-07-27
Field Trip Health Ltd. to Commence Trading on the NASDAQ on July 29, 2021 Under the Symbol FTRP
Field Trip Health to commence trading on the NASDAQ on July 27th under the symbol "FTRP".
TSI EDITOR |
2021-07-27
MINDCURE Launches Second Stage of Manufacturing Synthetic Ibogaine for Use in Psychedelic Clinical Research
MINDCURE's proprietary ibogaine manufacturing has reached the second stage of development: assessing the quality of its synthetic ibogaine.
TSI EDITOR |
2021-07-27
Substance Abuse: Global Plague, A Pot Of Gold For Psychedelic Stocks
We explain why addiction therapy likely offers the greatest long-term commercialization potential within the psychedelic drug industry.
TSI EDITOR |
2021-07-26
Red Light Holland Announces Updated Cash Position of Approximately $30 Million
Red Light Holland reports an updated position in cash and cash equivalents of roughly CAD$30 million following its merger with Creso Pharma.
TSI EDITOR |
2021-07-23
Levitee Labs Signs Definitive Agreements to Acquire Clinics, Pharmacies, and a Telemedicine Company in Alberta
Levitee Labs announces definitive agreements to acquire 3 specialized pharmacies, a "leading telehealth provider", and 5 addiction clinics.
TSI EDITOR |
2021-07-23
Latest Stories
NEW BULL MARKET ALERT
Psychedelics Have Proven Potential To Disrupt Entire Mental Healthcare Industry
Get Your Guide To “Ground Floor” Opportunity In Psychedelic Stocks Now